Title:
内皮細胞表面抗原を基礎とする腫瘍ワクチンの製造方法
Document Type and Number:
Japanese Patent JP5154641
Kind Code:
B2
Abstract:
The inventive method for producing an antitumoral vaccine using endothelial cells, consists in exposing live endothelial cells to a protease action which is vital therefor and in extracting the released surface antigens. The live endothelial cells are repeatedly treated with protease at intervals necessary for restoring the surface antigens by the cells, the surface antigens are accumulated until the dose thereof, necessary for vaccination, is obtained and the quality of the thus obtained vaccine is verified. Said invention makes it possible to increase the efficiency of oncological disease treatment by damaging tumoral vessels by overpassing the immune tolerance of the body to the endothelial cells of the tumoral vessels. The invention keeps in mind the overpassing of immune tolerance, in particular to activated endothelial cells, thereby making it possible to damage the immune system, in particular of tumoral vessels.
Inventors:
LOKHOV,Petr Genrievich
Application Number:
JP2010506113A
Publication Date:
February 27, 2013
Filing Date:
October 16, 2007
Export Citation:
Assignee:
LOKHOV,Petr Genrievich
International Classes:
A61K39/00; A61P35/00
Domestic Patent References:
| JP2005530856A |
Foreign References:
| WO2008108679A1 | ||||
| WO2005120558A1 | ||||
| US5030621 | ||||
| US5635188 | ||||
| US6338853 | ||||
| US5993829 |
Other References:
WEI,Y.Q. et al,Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine,Nat Med,2000年,Vol.6, No.10,p.1160-6
RODRIGUEZ-ORTEGA M J,NATURE BIOTECHNOLOGY,米国,NATURE PUBLISHING GROUP,2006年 2月,V24 N2,P191-197
WOLFERS,J. et al,Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming,Nat Med,2001年,Vol.7, No.3,p.297-303
BOCCHIA,M. et al,Antitumor vaccination: where we stand,Haematologica,2000年,Vol.85, No.11,p.1172-206
RODRIGUEZ-ORTEGA M J,NATURE BIOTECHNOLOGY,米国,NATURE PUBLISHING GROUP,2006年 2月,V24 N2,P191-197
WOLFERS,J. et al,Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming,Nat Med,2001年,Vol.7, No.3,p.297-303
BOCCHIA,M. et al,Antitumor vaccination: where we stand,Haematologica,2000年,Vol.85, No.11,p.1172-206
Attorney, Agent or Firm:
Hitoshi Shinbo